4-(哌啶-1-基磺酰)苯基硼酸 | 486422-58-6

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(哌啶-1-基磺酰)苯基硼酸
• 中文别名: 4-(哌啶基-1-磺酰基)苯硼酸；4-(1-哌啶基磺酰基)苯硼酸
• 英文名称: (4-(piperidin-1-ylsulfonyl)phenyl) boronic acid
• 英文别名: 4-(Piperidin-1-ylsulfonyl)phenylboronic acid；(4-piperidin-1-ylsulfonylphenyl)boronic acid
• CAS: 486422-58-6
• 化学式: C₁₁H₁₆BNO₄S
• 分子量: 269.129
• InChiKey: MIEADZYHESCCES-UHFFFAOYSA-N

物化性质

• 熔点：
  268-272

计算性质

• 辛醇/水分配系数(LogP)：
  -0.46
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  86.2
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2935009090
• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-(Piperidin-1-ylsulfonyl)phenylboronic acid
Product Name:
Synonyms: 1-(4-Boronophenylsulfonyl)piperidine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-(Piperidin-1-ylsulfonyl)phenylboronic acid
Ingredient name:
CAS number: 486422-58-6

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H16BNO4S
Molecular weight: 269.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(哌啶-1-基磺酰)苯基硼酸 、 N-(3-氯-4-((3-氟苄基)氧基)苯基)-6-碘喹唑啉-4-胺盐酸盐 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 为溶剂， 反应 18.0h， 以14.6%的产率得到N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(4-(piperidin-1-ylsulfonyl)phenyl)quinazolin-4-amine
  参考文献：
  名称：

  Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis

  摘要：

  Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns by using chemical scaffolds from drugs approved for other indications can speed up drug discovery for neglected diseases. We demonstrated recently that the 4-anilinoquinazolines lapatinib (GW572016, 1) and canertinib (CI-1033) kill T. brucei with low micromolar EC50 values. We now report promising activity of analogues of 1, which provided an excellent starting point for optimization of the chemotype. Our compound optimization that has led to synthesis of several potent 4-anilinoquinazolines, including NEU617, 23a, a highly potent, orally bioavailable inhibitor of trypanosome replication. At the cellular level, 23a blocks duplication of the kinetoplast and arrests cytokinesis, making it a new chemical tool for studying regulation of the trypanosome cell cycle.

  DOI：

  10.1021/jm400349k
• 作为产物：
  描述：

  1-(4-溴苯基磺酰)哌啶 在 正丁基锂 、 水 、 silica gel 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 4-(哌啶-1-基磺酰)苯基硼酸
  参考文献：
  名称：

  Discovery of Novel Potent and Highly Selective Glycogen Synthase Kinase-3β (GSK3β) Inhibitors for Alzheimer’s Disease: Design, Synthesis, and Characterization of Pyrazines

  摘要：

  Glycogen synthase kinase-3 beta, also called tau phosphorylating kinase, is a proline-directed serine/threonine kinase which was originally identified due to its role in glycogen metabolism. Active forms of GSK3 beta localize to pretangle pathology including dystrophic neuritis and neurofibrillary tangles in Alzheimer's disease (AD) brain. By using a high throughput screening (HTS) approach to search for new chemical series and cocrystallization of key analogues to guide the optimization and synthesis of our pyrazine series, we have developed highly potent and selective inhibitors showing cellular efficacy and blood-brain barrier penetrance. The inhibitors are suitable for in vivo efficacy testing and may serve as a new treatment strategy for Alzheimer's disease.

  DOI：

  10.1021/jm201724m

文献信息

• SUBSTITUTED NAPHTHYLACETIC ACIDS
  申请人：Hoffmann-La Roche Inc.

  公开号：US20130225588A1

  公开（公告）日：2013-08-29

  The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 and X are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

  这项发明涉及式(I)的化合物： 及其药学上可接受的盐，其中R 1 ，R 2 ，R 3 和X在详细说明和权利要求中有定义。此外，本发明涉及制造和使用式I的化合物的方法，以及含有这种化合物的药物组合物。式I的化合物是CRTH2受体的拮抗剂或部分激动剂，可能在治疗与该受体相关的疾病和紊乱方面有用，如哮喘。
• HETEROARYL DERIVATIVES AS ALPHA7 NACHR MODULATORS
  申请人：Sinha Neelima

  公开号：US20130331387A1

  公开（公告）日：2013-12-12

  Disclosed is a compound of formula (I), wherein Z, m and R 1 -R 6 are as described herein, as a modulator of nicotinic acetylcholine receptors particularly the α7 subtype, in a subject in need thereof, as well as analogues, prodrugs, isotopically substituted analogs, metabolites, pharmaceutically acceptable salts, polymorphs, solvates, isomers, clathrates, and co-crystal thereof, for use either alone or in combinations with suitable other medicaments, and pharmaceutical compositions containing such compounds and analogues. Also disclosed are a process of preparation of the compounds and the intended uses thereof in therapy, particularly in the prophylaxis and therapy of disorders such as Alzheimer's disease, mild cognitive impairment, senile dementia, and the like.

  公开的是一种具有式（I）的化合物，其中Z、m和R1-R6如本文所述，作为尤其是α7亚型的尼古丁乙酰胆碱受体的调节剂，在需要的受试者中使用，以及类似物、前药、同位素替代物、代谢物、药学上可接受的盐、多型体、溶剂合物、异构体、包合物和其共晶，可单独使用或与适当的其他药物组合使用，以及含有这种化合物和类似物的药物组合物。还公开了一种制备这些化合物的方法及其在治疗中的预期用途，特别是在预防和治疗阿尔茨海默病、轻度认知障碍、老年性痴呆等疾病中的用途。
• Design and Evaluation of Novel Biphenyl Sulfonamide Derivatives with Potent Histamine H₃ Receptor Inverse Agonist Activity
  作者：Jonathan A. Covel、Vincent J. Santora、Jeffrey M. Smith、Rena Hayashi、Charlemagne Gallardo、Michael I. Weinhouse、Jason B. Ibarra、Jeffrey A. Schultz、Douglas M. Park、Scott A. Estrada、Brian J. Hofilena、Michelle D. Pulley、Brian M. Smith、Albert Ren、Marissa Suarez、John Frazer、Jeffrey Edwards、Erin K. Hauser、Jodie Lorea、Graeme Semple、Andrew J. Grottick

  DOI：10.1021/jm900857n

  日期：2009.9.24

  Phenethyl-R-2-methylpyrrolidine containing biphenylsulfonamide compounds were shown to be potent and selective antagonists of the H3 receptor. Several of these compounds demonstrated in vivo activity in a rat model of (R)-α-methyl histamine (RAMH) induced dipsogenia, and one compound (4e) provided an increase in wakefulness in rats as measured by polysomnographic methods. However, more detailed analysis of the PK/PD

  组胺-H 3受体的拮抗作用是探索增加清醒性以治疗诸如过度日间嗜睡（EDS）以及其他睡眠或认知障碍之类的疾病的一种策略。含有苯乙基-R -2-甲基吡咯烷的联苯磺酰胺化合物被证明是H 3受体的有效和选择性拮抗剂。这些化合物中的几种在（R）-α-甲基组胺（RAMH）诱导的成瘾症的大鼠模型中具有体内活性，一种化合物（4e）通过多导睡眠监测法测量了大鼠的清醒度。但是，对PK / PD关系的更详细分析表明存在共同的活性代谢物，这可能会使该系列化合物无法进一步开发。
• [EN] NEW DERIVATIVES OF 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXAMIDE OR 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXYLIC ACID<br/>[FR] NOUVEAUX DERIVES DE 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXAMIDE OU D'ACIDE 5-ARYL-1H-PYRROLO [2, 3B] PYRIDINE-3-CARBOXYLIQUE
  申请人：ASTRAZENECA AB

  公开号：WO2006001754A1

  公开（公告）日：2006-01-05

  The present invention relates to new compounds of formula I as a free base or a pharmaceutically acceptable salt, solvate or solvate of salt thereof, a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.

  本发明涉及公式I的新化合物，可以是自由碱或药用可接受的盐、溶剂合物或其盐的溶剂合物，以及用于其制备的新中间体，包含所述治疗活性化合物的药物配方，以及所述活性化合合物在治疗中的应用。
• Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread
  作者：Manon Garcia、Laurent Hoffer、Raphaël Leblanc、Fatiha Benmansour、Mikael Feracci、Carine Derviaux、Antonio Luis Egea-Jimenez、Philippe Roche、Pascale Zimmermann、Xavier Morelli、Karine Barral

  DOI：10.1016/j.ejmech.2021.113601

  日期：2021.11

  syntenin PDZ domains interacting with syndecans. We therefore aimed to develop, through a fragment-based drug design approach, novel inhibitors targeting syntenin-syndecan interactions. We describe here the optimization of a fragment, ‘hit’ C58, identified by in vitro screening of a PDZ-focused fragment library, which binds specifically to the syntenin-PDZ2 domain at the same binding site as the syndecan-2

  Syntenin 刺激外泌体的产生，其表达在许多癌症中上调，并与转移性肿瘤的扩散有关。这些作用得到了与 Syndecans 相互作用的 Syntenin PDZ 域的支持。因此，我们的目标是通过基于片段的药物设计方法开发针对合成蛋白-合成蛋白聚糖相互作用的新型抑制剂。我们在这里描述了一个片段的优化，“命中” C58，通过体外筛选以 PDZ 为重点的片段库，它与 syntenin-PDZ2 域在与 syndecan-2 肽相同的结合位点特异性结合。X 射线晶体结构和计算对接被用来指导我们的优化过程并导致化合物45和57 (IC 50 = 33 μM 和 47 μM；分别），两个代表的 Syntenin-syndecan 相互作用抑制剂，它们选择性地影响 Syntenin-外泌体的释放。这些发现表明，有可能鉴定出抑制合成蛋白-合成多糖相互作用和外泌体释放的小分子，这些小分子可能对癌症治疗有用。